Lenvatinib Mesylate-impurities | Pharmaffiliates

lenvatinib mesylate

Lenvatinib is approved for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic, progressive, and did not respond to treatment with radioactive iodine. It is an anti-cancer drug. Reference standards of Lenvatinib Mesylate API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Lenvatinib Mesylate - API
    [catalogue_number] => PA 39 03000
    [category_ids] => ,79,80,78,70,82,88,
    [chemical_name] => 
    [weight] => 522.96
    [form] => C22H23ClN4O7S
    [cas] => 857890-39-2
    [pslug] => 857890-39-2-lenvatinib-mesylate-api-pa3903000
    [latest_product] => 0
    [linkproducts] => 1
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 39 03000

Lenvatinib Mesylate - API


  • Catalogue No.:PA 39 03000

  • CAS :

    857890-39-2

  • Molecular Formula : C22H23ClN4O7S

  • Molecular Weight : 522.96